|
|
|
Oramed Pharma 
|
6.85 1.32 (0.24%) |
01-25 16:00 |
Open: |
5.8 |
Pre close: |
5.53 |
Target:
|
8.68
|
High: |
7.43 |
Low: |
5.75 |
Resistance:
|
7.43
8.68 
|
Volume: |
2,940,833 |
Market Cap: |
183M |
Support:
|
5.32
4.02
|
|
|
|
Technical Analysis |
Moving Averages |
MA(5):
|
5.14
 |
MACD |
MACD(12,26):
|
0.37  |
MA(20): |
4.58  |
Signal(12,26,9): |
0.21  |
MA(100): |
3.40  |
Stochastic Oscillator |
%K(14,3):
|
86.17  |
MA(250): |
3.57  |
%D(3): |
71.63  |
Average Volume(K) |
3-Month: |
65597
|
52-Week |
High:
|
7.43 |
10-Days: |
63348 |
Low: |
2.40 |
RSI |
RSI(14):
|
83.94  |
Change(%): |
30.5 |
Financials, Statistics and Valuation |
EPS |
-0.561 |
Return on Equity (ttm) |
-44.0 |
Shares Out. (M) |
23.68 |
EPS Est. Current Year |
-0.780 |
Return on Assets (ttm) |
-18.5 |
Shares Float (M) |
21.01 |
EPS Est. Next Year |
-1.250 |
PEG Ratio |
0.00 |
% Held by Insiders |
13.90 |
EPS Est. Next Quarter |
-0.270 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
14.50 |
Forward EPS |
0.820 |
Gross Profit (p.s.) |
0.114 |
Shares Short (K) |
1110 |
Book Value (p.s.) |
1.390 |
EBITDA (p.s.) |
-0.496 |
P/E |
-12.21 |
Sales Per Share |
0.114 |
Qtrly Earnings Growth |
0.00 |
P/BV |
4.93 |
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-12.44 |
P/S |
59.85 |
Operating Margin |
-433.84 |
Levered Free Cash Flow
(M) |
-6.60 |
P/CF |
-13.04 |
|
|
|
|
|